Objective-To establish pharmacokinetic and pharmacodynamic properties of a
racemic mixture and individual R(-) and S(+) enantiomeric forms of ketoprof
en (KTP) in sheep and determine pharmacodynamic variables of KTP by pharmac
okinetic-pharmacodynamic modeling.
Animals-8 female Dorset crossbred sheep.
Procedure-A tissue cage model of inflammation was used. Carrageenan was adm
inistered into tissue cages. Time course of cyclooxygenase (COX)-2 inhibiti
on was determined in vivo by measurement of exudate prostaglandin E-2 (PGE(
2)) concentrations. Time course of COX-1 inhibition was determined ex vivo
by measurement of serum thromboxane B-2 (TXB2) concentrations. In addition,
plasma concentration-time course and penetration of KTP enantiomers into i
nflammatory exudate and transudate (noninflamed tissue cage fluid) were inv
estigated. Four treatments were compared: placebo, racemic mixture (rac-KTP
(3 mg/kg of body weight, [V]), S(+) KTP (1.5 mg/kg, IV), and R(-) KTP (1.5
mg/kg, IV).
Results-Both KTP enantiomers had elimination half-life and mean residence t
ime measurements that were short and volume of the central compartment and
steady state volume of distribution that were low. Clearance was rapid, par
ticularly for R(-) KTP Elimination of both enantiomers from exudate was > 1
0 times slower than from plasma. Both rac-KTP and the individual enantiomer
s significantly inhibited serum TXB2 concentrations for 12 hours. Rac-KTP a
nd S(+) KTP: but not R(-) KTP: also significantly inhibited PGE(2) synthesi
s in exudate for 12 hours.
Conclusions and Clinical Relevance-Inhibition of serum TXB2 concentration a
nd exudate PGE(2) synthesis for similar time courses after S(+) KTP adminis
tration indicates that it is a nonselective inhibitor of COX in sheep.